Formycon AG

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 16:35:29 14/02/2025 GMT			5-day change	1st Jan Change
49.80 ^EUR	-1.58%		-5.68%	-6.21%

02-05	Formycon's Partner Klinge Biopharma to Commercialize Eylea Biosimilar in Asia-Pacific	MT
02-05	Formycon Says Lotus Pharmaceutical Becomes Strategic Partner For Commercialization Of Formycon's Eylea®Biosimilar In Asia-Pacific Region	RE

Klinge Biopharma Signs License Deal for Formycon's Eylea Biosimilar

January 13, 2025 at 07:21 am

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Formycon AG

Formycon's Partner Klinge Biopharma to Commercialize Eylea Biosimilar in Asia-Pacific	02-05	MT
Formycon Says Lotus Pharmaceutical Becomes Strategic Partner For Commercialization Of Formycon's Eylea®Biosimilar In Asia-Pacific Region	02-05	RE
Formycon Ag Concludes an Exclusive License Agreement with Lotus Pharmaceutical	02-05	CI
FORMYCON : Receives a Buy rating from Hauck & Aufhauser	01-23	ZD
Formycon receives EU approval for biosimilar to Bayer eye drug	01-20	DP
Formycon stock rises after EU approval of ophthalmic drug	01-20	DP
Formycon's Eylea Biosimilar Gets EU Approval	01-20	MT
Formycon Receives EU Approval for FYB203 (Aflibercept), A Biosimilar to Eylea, Under the Brand Names Ahzantive and Baiama	01-20	CI
Borse Frankfurt-News: 2G Energy Top Seller (Small Caps)	01-16	DP
Formycon rises again after approval announcement	01-15	DP
Formycon, Fresenius Kabi Secure UK Medicines Regulator's Nod for Stelara Biosimilar	01-15	MT
Formycon AG and Fresenius Kabi Announce MHRA Approval for FYB202/Otulfi (Ustekinumab), Biosimilar to Stelara	01-15	CI
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment	01-13	MT
FORMYCON : RBC maintains a Buy rating	01-13	ZD
Klinge Biopharma Signs License Deal for Formycon's Eylea Biosimilar	01-13	MT
Teva Pharmaceuticals International GmbH Becomes Strategic Commercialization Partner for Formycon AG Biosimilar Candidate Fyb203 (Eylea/ Aflibercept) in Major Parts of Europe and Israel	01-13	CI
Formycon AG(XTRA:FYB) added to Germany TECDAX Index (Price Return)	01-12	CI
Formycon AG(XTRA:FYB) added to Germany TECDAX (Total Return) Index	01-12	CI
Formycon to Join Deutsche Börse's TecDAX Index	01-09	MT
Formycon, Fresenius Kabi Win Health Canada's Nod for Stelara Biosimilar	01-09	MT
Formycon AG(XTRA:FYB) added to Germany SDAX (Total Return) Index	12-22	CI
FORMYCON : RBC reiterates its Buy rating	12-10	ZD
Formycon Enters Commercialization Deal for Stelara Biosimilar in Middle East, North Africa	12-09	MT
German Stocks Shrug Off Worsening Construction Slump	12-05	MT
Formycon to Become Part of Germany's SDAX Index	12-05	MT

Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.

Employees

239

Sector

Biotechnology & Medical Research

Calendar

31/03/2025 - Metzler Small Cap Days

More about the company